Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok2. fázis

Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma

A legfontosabb adatok

Ki végzi
M.D. Anderson Cancer Center
Hol
Houston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
26 fő, tervezett
Kezdés
2027. ápr. 29.
Várható befejezés
2031. jan. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Vorasidenib
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki nem vehet részt

  • Prior treatment with an IDH inhibitor
  • Participants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study
  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 2 with the exception of alopecia
  • Participants who are receiving any other investigational agents
  • Concomitant use of strong CYP3A4 inducers or inhibitors, or medications with potential for significant drug-drug interactions with vorasidenib as detailed in the prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf)
  • Examples of such agents or substances include those that interact through the CYP450 isoenzyme system or other sources of drug interactions (e.g., P-glycoprotein). Specifically excluded substances may be listed below and presented as an appendix. If appropriate, the following text concerning CYP450 interactions may be used or modified; Note: This must account for all agents to be used in this study, including commercial agents. Please refer to the FDA product labels for all commercial agents and include information on prohibited concomitant medications in all applicable sections of the protocol
  • Pregnant women are excluded from this study because vorasidenib is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorasidenib, breastfeeding should be discontinued if the mother is treated with vorasidenib. These potential risks may also apply to other agents used in this study
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to [list out Agent(s)] or other agents used in study
  • Participants with uncontrolled intercurrent illness (Indicate clearly what type or extent)
  • Human immunodeficiency virus (HIV)-infected Participants are excluded, except those on effective ART with undetectable viral load, who are eligible
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements
  • The investigator(s) must state a medical or scientific reason if Participants who are cancer survivors will be excluded from the study
  • Participants with active brain metastases. The investigator(s) must state a medical or scientific reason if Participants who have brain metastases will be excluded from the study

Egyéb feltételek

  • Eligibility Criteria
  • Patients with diagnosis of unresectable or metastatic iCCA (confirmed by treating clinician) who have received at least one first-line standard of care systemic therapy for iCCA
  • Patients must have received a standard first-line therapy (as per NCCN guidelines) for cholangiocarcinoma/ biliary cancer
  • Presence of an IDH2 mutation confirmed by laboratory testing using validated methods, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS)
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam
  • Age ≥18 years
  • ECOG performance status ≤2 (Karnofsky ≥60%,)
  • Patients must have adequate organ and marrow function as defined below:; absolute neutrophil count ≥1,000/mcL; platelets ≥75,000/mcL; total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN; Creatinine ≤ institutional ULN
  • For Participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable
  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For Participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, Participants should be class 2B or better
  • The effects of vorasidenib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:; Postmenopausal (no menses in greater than or equal to 12 consecutive months); History of hysterectomy or bilateral salpingo-oophorectomy; Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy); History of bilateral tubal ligation or another surgical sterilization procedure
  • Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and not donate sperm for the duration of study participation, and 4 months after completion of vorasidenib administration
  • Ability to understand and the willingness to sign a written informed consent document

Helyszínek itt: Egyesült Államok

  • UT MD Anderson Cancer CenterHouston, Egyesült ÁllamokContact: Milind Javle, MDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.

A vizsgálat csoportja

  • Safety Run-In/ExpansionA vizsgált kezelés

    Treatment with Vorasidenib (PO) Q4W

    Kezelés: Vorasidenib

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. november 16.